Proteon Therapeutics, Inc. (PRTO) Receives “Hold” Rating from Robert W. Baird
Robert W. Baird reaffirmed their hold rating on shares of Proteon Therapeutics, Inc. (NASDAQ:PRTO) in a report released on Friday morning. Robert W. Baird currently has a $2.00 target price on the biopharmaceutical company’s stock.
A number of other brokerages have also recently commented on PRTO. Zacks Investment Research cut Proteon Therapeutics from a strong-buy rating to a hold rating in a research report on Wednesday, October 18th. HC Wainwright set a $2.00 price target on Proteon Therapeutics and gave the stock a hold rating in a research report on Wednesday, August 9th. Oppenheimer Holdings, Inc. restated a market perform rating on shares of Proteon Therapeutics in a research report on Wednesday, August 16th. Finally, Cowen and Company restated a hold rating on shares of Proteon Therapeutics in a research report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of $6.13.
Proteon Therapeutics (NASDAQ PRTO) opened at $1.85 on Friday. Proteon Therapeutics has a 12-month low of $1.10 and a 12-month high of $11.45.
WARNING: “Proteon Therapeutics, Inc. (PRTO) Receives “Hold” Rating from Robert W. Baird” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/proteon-therapeutics-inc-prto-receives-hold-rating-from-robert-w-baird/1701697.html.
An institutional investor recently bought a new position in Proteon Therapeutics stock. RA Capital Management LLC acquired a new stake in Proteon Therapeutics, Inc. (NASDAQ:PRTO) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,337,462 shares of the biopharmaceutical company’s stock, valued at approximately $2,040,000. Proteon Therapeutics makes up about 0.2% of RA Capital Management LLC’s holdings, making the stock its 22nd biggest holding. RA Capital Management LLC owned approximately 7.59% of Proteon Therapeutics at the end of the most recent reporting period. 49.93% of the stock is owned by institutional investors and hedge funds.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.